Sharing some answers to some questions from PIQ

For what it's worth, and following on from an earlier post where someone suggested the company does not respond to calls or emails (I found the opposite to be true) I am sharing their response to my question from a couple of weeks ago. If you have any specific questions, contact James Moses, their Investor Relations person. Hope this helps some of my fellow investors sleep a little better at night.


1. Regarding the validation study announced on the 7th of march, when can we expect results?
Results of the validation study will be released once they become available. The Company is mindful of the market's anticipation of these results and it is a key focus for the Company. Key to the overall process of the validation study is to ensure that the assessment and interpretation of the findings of the study is carried out with complete thoroughness so as to provide a full picture in terms of the results. As you would appreciate, the Company needs to take the appropriate amount of time required to complete this process, and is working to deliver the results in as timely a manner as possible.

2. Will a positive result lead with any certainty to a licencing contract with the company that requested the validation?
A positive result will add a major body of additional weight to the validation of PromarkerD, and would deliver, in total, a study patient cohort of around 950 (including this and original study cohort). This size study patient sample (assuming positive results) would provide potential partners with a strong body of statistical data and results, which the Company believes would be of major benefit in its ongoing licensing and partnering discussions.

3 Are you free to disclose whom you are negotiating with, and the progress level of the negotiations ?
Not at this point in time, which is common when dealing with global pharma and healthcare companies in these types of situations. The Company will continue to provide updates via ASX announcement on the progress of this and other activities.

4. Have the international marketing efforts for Promarker D lead to any new concrete leads which are currently in negotiation?
Yes, the Company continues to market PromarkerD aggressively and has a number of current licensing and partnering discussions on-foot in different global markets, which is highly exciting. The Company will, as a matter of course, formally update the market on any material progress on any of its partnering opportunities for PromarkerD.

5. Do you have any other products approaching commercial viability in the near term future?
PromarkerD remains the lead candidate and core focus from a commercialisation perspective, and given the strong potential the Company sees in PromarkerD as a predictive and diagnostic test for diabetic kidney disease, it will continue to remain at the forefront of its commercialisation activities. At the same time, the Company's analytical services operations continues to derive regular ongoing revenue for the Company, and growing revenues from this area of the business is a core continuing focus for PIQ. It also has a focus on pursuing other biomarker discovery opportunities in other diseases/conditions.

6. Regarding the recent expansion into the Indian market, do you expect to establish a physical presence there or simply have an agency through a local sales representative. If it is the latter, how will that work for your analytical services?
The Company has appointed a Sales Manager for the Indian market as a member of staff. Based in Delhi, they are responsible for driving new business opportunities for the Company in the massive Indian biotech market. This appointment is a key plank of the Company's growth plans in the Indian market and is a strong positive for the growth of the analytical services business in India

7. Have there been any outcomes from the presentation to bio-analytical sector in the USA last month.
The Company's presentations during its recent US business development trip were very well received and served to enhance the awareness of the Company and the appreciation of its suite of proteomics-based services. As a result of this, and its other ongoing marketing activities, the Company has a number of potential new business opportunities across the various areas of its business. As mentioned above, it will update the market on any material progress on any of these opportunities.